CordenPharma Expands Service Offerings

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016
Volume 11
Issue 7

The company expanded its services to include oligonucleotide API development and manufacturing and received approval for its Caponago manufacturing facility.

On July 1, 2016, CordenPharma announced that it has expanded its services to include oligonucleotide API development and manufacturing. The investment was initiated by CordenPharma Colorado and is expected to be complete before the end of 2016, the company said in a press announcement. Corden’s portfolio for API and drug products includes peptides, lipids, and carbohydrates for API manufacturing and development. In late June, the Italian Medicines Agency approved Corden’s sterile injectable facility in Caponago, Italy. The manufacturing facility, which was recently completed, will support customer development and commercial programs by providing service in aseptic filling of liquid and lyophilized vials, and pre-filled syringes. This adds to the facility’s existing terminal sterilization capabilities.

Source: Corden Pharma

Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content